Resilience Secures $17.5M in Federal Funding to Boost U.S. Production of Critical Medicines

URLhttps://biopharmaapac.com/news/28/5343/resilience-
SourceBioPharmaAPAC
Date Published10/04/2024

Additional Reshoring Information:

Company/Division name National Resilience w Aralez Bio
Type of work Manufacturing
Reshoring category:Reshoring
Year reshoring announced:2024
Year reshoring implemented or to be implemented:2024
Capital investment ($):17.5
If relevant, work nearshored to:-
Industry(ies):Chemicals
Product(s) reshoredpharma ingredients
What non-domestic negative factors made offshoring less attractive?Supply chain interruption
What domestic positive factors made reshoring more attractive?Eco-system synergies, Government Incentives, Higher productivity, Image/brand, Manufacturing/engineering joint innovation (R&D), Proximity to customers/market, Skilled workforce availability/training
Find Reshoring Articles